Tinaquant Lipoprotein a Gen.2 5852633190Recalls & reported problems
Roche Diagnostics GmbH · Class 2
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 04015630930586), received between Feb 21, 2025 and Mar 24, 2026 — classified as 2 malfunctions.
The most frequently reported specific device problem is “Low Test Results” (2 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Reports received per month
Most reported problems
Device problems
- Low Test Results2
- Non Reproducible Results2
- Chemical Problem1
Patient problems
- No Clinical Signs, Symptoms or Conditions2
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
MalfunctionMar 24, 2026Low Test Results; Non Reproducible Results
THE INITIAL REPORTER COMPLAINED OF A DISCREPANT LOW RESULT FOR 1 PATIENT SAMPLE TESTED FOR TINA-QUANT LIPOPROTEIN (A) GEN.2 (LPA2) ON A COBAS 8000 COBAS C 701 MODULE. THE INITIAL RESULT WAS 236 NMOL/L. THIS RESULT WAS QUESTIONED BY THE PHYSICIAN, AND THE SAMPLE WAS REPEATED. THE REPEAT RESULT WAS 248.0 NMOL/L, ACCOMPANIED BY AN INVALIDATING DATA FLAG. THE REPEAT RESULT WAS 1213.5 NMOL/L. THE SAMPLE WAS REPEATED WITH A 1:3 DILUTION, AND THE RESULT WAS 1206.0 NMOL/L, ACCOMPANIED BY AN INVALIDATING DATA FLAG. THE SAMPLE WAS REPEATED WITH A 1:5 DILUTION, AND THE RESULT WAS 1431.5 NMOL/L, ACCOMPANIED BY AN INVALIDATING FLAG. THE SAMPLE WAS REPEATED WITH A 1:20 DILUTION, AND THE RESULT WAS 951.1 NMOL/L.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24681101 ↗MalfunctionFeb 21, 2025Low Test Results; Chemical Problem; Non Reproducible Results; Low Test Results; Chemical Problem; Non Reproducible Results
THERE WAS AN ALLEGATION OF A QUESTIONABLE TINA-QUANT LIPOPROTEIN (A) GEN.2 RESULT FROM THE COBAS 8000 ISE 1800 MODULE. THE INITIAL RESULT WAS 230 NMOL/L, AND THE REPEAT RESULT ON A SIEMENS ANALYZER WAS 579 NMOL/L. THERE WAS ANOTHER TEST COMPLETED ON THE C 701 FROM THE SAME SAMPLE WITH DILUTION THAT GAVE A RESULT OF > TEST. THE QUESTIONABLE RESULT WAS REPEATED BECAUSE IT DID NOT MATCH THE PREVIOUS RESULTS. THE RESULTS OF 579 NMOL/L MATCHED WITH PREVIOUS RESULTS.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 21433840 ↗
Other LIPOPROTEIN, LOW-DENSITY, ANTIGEN, ANTISERUM, CONTROL devices
- Lp (a) LP3403Randox Laboratories Limited · Lipoprotein, Low-Density, Antigen, Antiserum, Control1 recall0 reports
- Lp (a) LP2757Randox Laboratories Limited · Lipoprotein, Low-Density, Antigen, Antiserum, Control1 recall0 reports
- Tina-quant Lipoprotein (a) Gen.2 08106126190Roche Diagnostics GmbH · LIPOPROTEIN, LOW-DENSITY, ANTIGEN, ANTISERUM, CONTROL28 reports
- Tinaquant Lipoprotein a Gen.2 5852625190Roche Diagnostics GmbH · LIPOPROTEIN, LOW-DENSITY, ANTIGEN, ANTISERUM, CONTROL1 report
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page